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Abstract
Background Graves’ ophthalmopathy (GO) is thought to be
an inflammatory disorder of autoimmune background. The
aim of this study is to investigate the involvement of vascular
endothelial growth factor (VEGF) and basic fibroblast growth
factor (b-FGF) in patients with Graves’ ophthalmopathy
(GO).
Methods Serum concentrations of VEGF and b-FGF of 48
GO patients, 30 Graves’ hyperthyroid disease (GD) patients
without ophthalmopathy, and 30 healthy controls were mea-
sured by Enzyme-Linked Immunosorbent Assay (ELISA).
Patients with GO were subdivided into two groups according
to clinical activity scores (CAS): a score of 3 or less is
considered as inactive (CAS≤3, inactive GO, n=14), and 4
or more is considered active eye disease (CAS≥4, active GO;
n=34). All of the patients with active GO underwent cortico-
steroid therapy.
Results The concentrations of serum VEGF and b-FGF were
significantly higher in patients with GO and in those with GD
than in controls. The serum levels of VEGF and b-FGF in
patients with active GO were higher than those in patients
with inactive GO and those in GD patients (P<0.05). More-
over, serum VEGF and b-FGF concentratison were signifi-
cantly correlated with CAS in GO patients (p<0.01). Mean
VEGF and b-FGF levels in corticosteroid-responsive patients
(CAS decreases ≥3 after treatment) decreased significantly
after corticosteroid treatment (P<0.05), and these changes
were accompanied by a decrease of CAS (P<0.05).
Conclusion The results suggest that serum VEGF and b-FGF
levels were increased in patients with active GO and could
reflect the degree of ocular inflammatory activity.
Keywords Vascular endothelial growth factor . Basic
fibroblast growth factor . Graves’ ophthalmopathy . Growth
factors . Inflammatory disorder
Introduction
Graves’ ophthalmopathy (GO), also known as thyroid-
associated ophthalmopathy (TAO), is thought to be an inflam-
matory disorder of autoimmune background, although the
pathophysiology of GO remains unclear. GO manifests as
orbital inflammation and expansion of fat and extraocular
muscles. Orbital T cells, fibroblasts, adipocytes, and perhaps
other residential cells release numerous cytokines, growth
factors including Vascular endothelial growth factor
(VEGF), basic fibroblast growth factor (b-FGF), and inflam-
matory mediators, many of which act as potent stimulators of
glycosaminoglycan accumulation and edema formation [1].
VEGF and b-FGF are potent angiogenic factors whose
activities include endothelial cell and fibroblast survival, pro-
liferation, migration, and tube formation [2]. VEGF and b-
FGF are critical mediators of physiological as well as patho-
logical angiogenesis. Increased b-FGF and VEGF levels have
been reported in several inflammatory diseases [3, 4]. During
inflammation, the presence of VEGF and b-FGF has been
associated with more intense accumulation of leukocytes
and exacerbation of injury [5–7]. Zittermann SI et al. [8]
demonstrated that b-FGF has direct and acute effects on
normal tissue that synergistically enhance recruitment of poly-
morphonuclear leucocytes, monocytes, and Tcells in response
to inflammatory cytokines and delayed type hypersensitivity
reactions, independent of angiogenesis. They also reported
VEGF and b-FGF differentially enhance monocyte and neu-
trophil recruitment to inflammation [9]. More recently, Matos
et al. [10] has found a positive immunohistochemical expres-
sion of VEGF and b-FGF in extraocular rectus, orbital fibrous,
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and adipose tissue of GO patients. Thus, this study was further
carried out to investigate the serumVEGF and b-FGF levels in
GO patients and evaluate the association between the serum
concentrations of VEGF and b-FGF and the degree of ocular
inflammatory activity of GO.
Subjects and methods
The study was carried out in three groups of subjects. One
group had 48 patients with clinical symptoms of
ophthalmopathy (GO). Patients who had had prior treatment
with steroids or radiation were excluded. Ophthalmopathy
was diagnosed by performing a complete eye examination,
and the clinical activity of GO was scored according to the
clinical activity score (CAS) suggested by Mourits et al. [11]
(Table 1). The extraocular muscle (EOM) involvement was
evaluated as positive when the patient had diplopia on a
binocular single vision test and corresponding extraocular
muscle enlargement on the computerized tomography (CT)
scan. According to CAS, patients with GO were subdivided
into two groups: a score of 3 or less was considered inactive
(CAS≤3, inactive GO, n=14), and 4 or more was considered
active eye disease (CAS≥4, active GO; n=34). The clinical
severity of active GO was scored according to the
ophthalmopathy index (OI) based on the NOSPECS classifi-
cation. All the patients with active GO underwent corticoste-
roid therapy consisting of intravenous infusions of methyl-
prednisolone (MP) in two series of 3 g each session for
2 weeks and subsequent treatment with oral prednisone (P)
at 60 mg per day for two months and then a gradual tapering
schedule with a reduction of 5 mg per week by 14weeks). The
serum samples were collected 24 h before MP and at the end
of corticosteroid therapy. The second group had 30 patients
with Graves’ disease (GD) without symptoms of
ophthalmopathy. Both GO and GD patients were euthyroid
before the study. Euthyreosis was confirmed by thyrotropin
and free thyroxine estimation. All of the patients of both of
these groups were treated with thiamazol. None had any other
autoimmune-related disease. The third group had 30 healthy
volunteers (control group) age-matched and sex-matched to
group 1 and 2 who had neither family history of Graves’
disease nor other autoimmune diseases. No acute infections
were observed in the GO, GD, and control subjects
three weeks prior to the study. In all cases, a written informed
consent was obtained from the patients. This study was ap-
proved by the Local Hospital Bioethical Committee.
All the sera samples were obtained at 8:00 AM after an
overnight fast and kept frozen at −80°C until used. The levels
of serum b-FGF and VEGF were determined by the ELISA
method (Parameter kit, Bender Med Systems, Vienna, Aus-
tria): b-FGF (sensitivity 30pg/ml; intra-assay precision 10%,
inter-assay precision 10%) and VEGF (sensitivity 14pg/ml;
intra-assay precision 6.8%, inter-assay precision 8.3%). The
levels of serum TSH receptor antibody (TRAB) were also
measured.
The statistical package SPSS 13 (SPSS Inc, Chicago, IL,
USA) was used for analysis. Values were expressed asMean ±
Standard Deviation (SD). One-way ANOVA (adjusted by
Bonferroni correction) was applied for multiple comparisons
of data, while the Student’s t test was used for pairwise
comparisons. The correlation of CAS with b-FGF and VEGF
levels were evaluated with a Spearman correlation test. Sta-
tistical significance was defined as P<0.05.
Results
GO patients, GD patients, and control subjects
Thirty-four patients with active GO, 14 patients with inactive
GO, 30 GD patients without ophthalmopathy but with dura-
tion of disease from 3–24 months, and 30 healthy control
subjects were studied. Their age, sex, CAS scores,
ophthalmopathy duration (the time from eye disease symptom
onset to sampling for each of the groups), exophthalmometry,
TRAb, and OI are summarized in Table 2. There was no
statistical difference in age or sex between the groups.
Increased serum concentration of b-FGF and VEGF in GO
The levels of serum b-FGF and VEGF are shown in Table 3.
We found a significantly higher level of b-FGF and VEGF in
the GD and GO groups than in the control group (P<0.05).
The serum levels of b-FGF and VEGF in GOwere higher than
in GD (P<0.05); the serum levels of b-FGF and VEGF in
Table 1 The 10 items of the clinical activity score (CAS)
Pain 1 Painful, oppressive feeling on or behind the globe
during the last 4 weeks
2 Pain on attempted up, side, or down gaze during the last
4 weeks
Redness 3 Redness of the eyelid(s)
4 Diffuse redness of the conjunctiva, covering at least one
quadrant
Swelling 5 Swelling of the eyelid(s)
6 Chemosis
7 Swollen caruncle




9 Decrease of eye movements in any direction ≥5° during
a period of 1–3 months
10 Decrease of visual acuity of ≥1 line(s) on the Snellen
chart (using a pinhole) during a period of 1–3 months
For each item present, one point is given. The sum of these points is the CAS
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active GO cases were higher than those in inactive GO cases
and in GD cases (P<0.05). However, the serum concentra-
tions of b-FGF and VEGF were not significantly different
between inactive GO cases and GD cases (P>0.05).
Serum concentration of b-FGF and VEGF in patients
with active GO after corticosteroid treatment
The serum b-FGF and VEGF levels during corticosteroid
treatment in patients with active GO are shown in Table 4. A
CAS change greater or equal to 3 after treatment is
considered as corticosteroid-responsive, and a change of
less than 3 was considered corticosteroid-resistant. There
were significant differences in serum b-FGF and VEGF
levels between the corticosteroid-responsive patients (n=
25) and the corticosteroid-resistant individuals (n=9).
The pre-treatment b-FGF and VEGF levels were signif-
icantly elevated in the corticosteroid-responsive patients
compared with the corticosteroid-resistant subjects
(P<0.05). In corticosteroid-responsive patients, b-FGF
Table 2 Characteristics of GO patients, GD patients, and control participants (mean ± SD)
Active GO Inactive GO GD Normal control P value
N 34 14 30 30
Sex (female:male) 23:11 9:5 19:11 20:10 0.62
Age (years) 31.06±15.15 30.79±17.80 34.50±13.45 32.8±10.8 0.60
Ophthalmopathy duration 10.06±7.16 12.64±10.78 0.88
CAS 5.65±1.72 2.57±0.65 NA NA <0.001
TSH (μIU/ml) 0.94±2.46 1.48±2.67 1.23±2.07 NA 0.34
Free T4 (ng/dl) 1.61±0.92 1.52±0.87 1.45±0.79 NA 0.72
Exophthalmos (mm) 19.5±2.76 17.31±2.51 NA NA 0.03
OI 8.35±1.28 5.71±1.54 NA NA 0.000
TRAb 638.37±261.34 423.03±190.94 356.11±160.56 NA 0.008
NA not applicable
Table 3 Serum b-FGF and VEGF concentrations in GO patients (active GO and inactive GO), GD patients, and the control group (NC) (mean±SD)
Growth factors Active GO (n=34) Inactive GO (n=14) GD (n=30) Normal control (n=30)
VEGF(pg/ml) 182.76±75.17c e 132.34±42.19b 125.46±34.82c d 76.45±6.81f
b-FGF(pg/ml) 101.52±35.53c e 78.58±17.37a 75.38±13.53b d 63.71±7.40e
–vs. controls, aP<0.05, bP<0.01, cP<0.001;
–vs. Inactive GO, dP>0.05, eP<0.05, fP<0.01;
Table 4 Serum b-FGF and
VEGF levels in patients with ac-












b-FGF (pg/ml) Corticosteroid-responsive (n=25) 124.61±38.30a c e 78.00±14.19d
Corticosteroid-resistant (n=9) 100.23±41.62b e 91.07±38.54
Inactive GO (n=14) 78.58±17.37
VEGF (pg/ml) Corticosteroid-responsive (n=25) 250.58±71.69a c e 133.46±34.97d
Corticosteroid-resistant (n=9) 192.58±53.24b e 163.57±44.79
Inactive GO (n=14) 132.34±42.19
CAS Corticosteroid-responsive (n=25) 7.50±2.61a c e 2.54±1.12d
Corticosteroid-resistant (n=9) 4.08±1.98b e 3.21±1.56
Inactive GO (n=14) 2.57±0.65
OI Corticosteroid-responsive (n=25) 9.75±1.83a c e 4.63±1.02
Corticosteroid-resistant (n=9) 7.82±1.13b e 4.51±1.18
Inactive GO (n=14) 5.71±1.54
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and VEGF levels were significantly decreased after the
treatment (P<0.05), and these changes were accompa-
nied by a decrease of CAS (P<0.05). There were no
differences in the post-treatment b-FGF and VEGF levels
between the corticosteroid-responsive patients and the
cor t i cos t e ro id - re s i s t an t sub j ec t s (P > 0.05 ) . In
corticosteroid-resistant patients, the pre-treatment b-FGF
and VEGF levels were higher than in patients with
inactive GO (P<0.05).
Correlation between disease activity and growth factors
There were significant correlations of CAS with
exophthalmometry (p<0.001) in patients with either active
or inactive GO. The positive correlation of CAS with b-FGF
in GO patients was shown in Fig. 1. Serum VEGF concentra-
tion had a significant correlation with CAS in GO patients
(p<0.01) (Fig. 2). Moreover, significant correlations between
b-FGF and VEGF (r=0.61, p<0.05) were noted. The elevated
Fig. 1 Correlation between
clinical activity score (CAS) and
serum b-FGF
Fig. 2 Correlation between
clinical activity score (CAS) and
serum VEGF
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levels of bFGF, VEGF, and CASwere all positively correlated
with TRAb (r1=0.37, p<0.01; r2=0.27, p<0.05; r3=0.72,
p<0.01).
Discussion
GO is an autoimmune condition characterized by infiltration
of the extraocular muscles (EOM) and/or the orbital fat/
connective tissue by lymphocytes and other mononuclear
cells. Recruitment of leukocytes from the blood into orbit is
a critical process in inflammation and immune responses.
Many diseases characterized by leukocyte infiltration are as-
sociated with both angiogenesis and the presence of b-FGF
and VEGF in the tissue [12].
We attempted to determine whether serum VEGF and b-
FGF increase in GO, which correlates with disease activity.
The sequential increase of VEGF and b-FGF concentrations in
the normal group, the GD patient group, or inactive GO
patient group, and the active GO patient group suggests that
VEGF and b-FGF may play a role in GO through the recruit-
ment of the effector leukocytes into the inflamed tissue sites,
thus orchestrating the immune response at the site of inflam-
mation. The CAS in GO was significantly correlated with
serum VEGF and b-FGF concentrations. Moreover, b-FGF
and VEGF levels were significantly decreased in
corticosteroid-responsive patients after corticosteroid treat-
ment, and these changes were accompanied by a decrease of
CAS. Thus, our data further suggest that VEGF and b-FGF
may have a relevant role in the inflammatory phenomenon
seen in GO.
b-FGF, produced by endothelial cells and fibroblasts, is one
of the most potent stimulators of angiogenesis and is mito-
genic and chemotactic for both endothelial cells and fibro-
blasts [13–15]. Inflammatory cytokines have been reported to
induce b-FGF synthesis [16, 17]. The expression and secretion
of b-FGF is increased at sites of inflammation. b-FGF is
increased in the serum and affected tissue of patients with
rheumatoid arthritis, inflammatory bowel disease, or asthma
[18–21]. Zittermann SI et al. [22] demonstrated that b-FGF
increases the recruitment of monocytes, T cells, and polymor-
phonuclear neutrophils to inflammatory dermal sites. Strong
immunoexpression of b-FGF has been found in the orbit
fibroblasts of patients with GO [10]. In this study, the serum
concentration of b-FGF was found to significantly increase in
GO patients, especially in those with active GO. We consider
that this release could occur because of orbit fibroblast dam-
age. This local release of b-FGF may normally lead to fibro-
blast proliferation and secretion of collagen and
glycosaminoglycans.
VEGF is produced by endothelial cells, macrophages, ac-
tivated T cells, and a variety of other cell types [2]. It was
originally identified as a potent enhancer of vascular perme-
ability [23], and this could account for the increased leukocyte
recruitment [24]. Ito [25] reported the presence of VEGF
mRNA-expressing cells scattered in edematous stroma, sug-
gesting that plasma cells may play an important role in the
development of edema in chronic inflammation via the pro-
duction of VEGF. Overexpression of VEGF mRNA by infil-
trating mononuclear cells has been found in delayed hyper-
sensitivity reactions [26]. Reports also suggest that VEGF acts
as an angiogenic mediator in rheumatoid arthritis [27, 28].
Strong immunoexpression of VEGF has been found in the
orbit endothelial cells of patients with GO [10]. Figueroa
et al. [29] found that levels of VEGF tended to be higher in
patients with active GO (n=13) compared with GD patients
(n=18) and patients with inactive GO (n=13), though no
significant differences were reached.The present study with
a higher number of patients was further conducted. On the basis
of the significantly increased VEGF levels in the patients with
GO, VEGF may be expected to play an important role in the
regulation of orbital inflammation in GO.
In conclusion, we demonstrated that the serum VEGF and
b-FGF levels were elevated in patients with increased inflam-
matory signs, and that successful management of active GO
with corticosteroids was associated with a decrease in these
two growth factors. Serum VEGF and b-FGF levels might
play a role in the acute phase of inflammation and could reflect
the degree of ocular inflammatory activity in GO patients.
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